From OHC

March 4, 2021

Contact: Joanie Manzo
Director, Marketing & Physician Services
513-751-2145 x10143

MYLUNG to deepen understanding of barriers and address challenges to improve care for lung cancer patients, including those with targetable mutations

OHC, a practice in The US Oncology Network, has joined the MYLUNG consortium, a large-scale research study to advance precision medicine options for patients with non-small cell lung cancer (NSCLC) who are being treated in the community. NSCLC is the most common type of lung cancer according to the American Cancer Society, accounting for about 84 percent of lung cancer cases.

The MYLUNG consortium, or “Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium,” will observe up to 12,000 community-based, metastatic NSCLC patients over a five-year period in one of the first broad, collaborative, research endeavors in lung cancer. In particular, MYLUNG aims to deepen understanding of molecular testing barriers to improve care for lung cancer patients, including those with mutations who may benefit from receiving precision medicine, the practice of leveraging targeted therapies across the continuum of care, as well as expand the opportunity for patients to participate in clinical trials.

“Many patients are not receiving the molecular testing they need to initiate targeted therapy early in their cancer care journey due to long timeframes, lack of coverage or another factor. This testing is critical to determine the patient’s cancer at a molecular level, so oncologists can create a more targeted and precise treatment plan,” said Robert L. Coleman, MD, FACOG, FACS, chief scientific officer, US Oncology Research. “In order to fulfill the promise of precision medicine for NSCLC patients, we need a fuller understanding of the barriers, challenges, risks and opportunities around molecularly-guided therapies. MYLUNG, with the help of OHC, will draw insights from these datasets that can lead to better therapy for patients in a timelier manner.”

“There are more treatment options than ever before for patients with NSCLC. This important study will deepen our understanding of the disease, allowing us to identify the optimum molecular testing and treatment protocol, and advancing hope for future lung cancer patients,” said David M. Waterhouse, MD, MPH, medical oncologist, hematologist, co-director of the department of clinical research at OHC and principal investigator for OHC’s lung cancer clinical trials.

The MYLUNG consortium brings together several healthcare providers like OHC with life sciences companies including Amgen, Eli Lilly and Company and Mirati Therapeutics, along with several McKesson-supported organizations focused on transforming and enhancing the cancer care experience including The US Oncology Network, US Oncology Research, and Ontada™ – McKesson’s new oncology technology and insights business.

MYLUNG will consist of three protocols over a five-year period:

  • Protocol 1 retrospectively reviews real-world data from Ontada’s iKnowMed℠ electronic health records (EHRs) of about 3,500 patients treated by providers in The US Oncology Network to understand baseline data on molecular testing across practices and identify historical barriers to testing and precision medicine in community practice.
  • Protocol 2, enrolling about 1,000 patients from approximately 10 practices, will monitor the real-world patient journey from presentation through their first line of cancer therapy, focusing on how diagnostic biomarker information is obtained, utilized and operationalized in decision-making. Patients are currently being enrolled into Protocol 2.
  • Protocol 3 will serve as a platform upon which prospectively assessed interventional strategies in patient-engagement algorithms will be conducted. Up to 7,500 patients from approximately 20 participating practices will be recruited over a five-year period. The individual clinical trials will integrate findings from the previous protocols and explore new processes and associated outcomes to help providers make the best treatment recommendations based on the data available and improve access to testing and appropriate therapies for NSCLC patients.

MYLUNG is poised to support meaningful progress and innovation in care delivery and potentially touch and improve thousands of lives.

“Participating in this national study underscores OHC’s commitment to providing our patients with early access to advanced treatment options and individualized care,” said Dr. Waterhouse. “In doing so, we give patients a wonderful sense of hope and possibly much more. Findings from MYLUNG will help to establish standards of care not only locally, but across the nation.”

OHC (Oncology Hematology Care), the region’s leading experts in the treatment of nearly every form of adult cancer and complex blood disorders, has been fighting cancer on the front lines for more than 35 years. OHC offers the latest medical, gynecologic and radiation therapy, and is always seeking better treatment options through its nationally recognized clinical trials program. OHC is the first certified adult cancer practice in the Cincinnati area to offer the ground-breaking CAR T-cell therapy for adults. For more information about OHC, or for a second opinion, call 1-888-649-4800 or visit

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *